News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,542 Results
Type
Article (13560)
Company Profile (110)
Press Release (246872)
Section
Business (87933)
Career Advice (461)
Deals (15323)
Drug Delivery (63)
Drug Development (36522)
Employer Resources (49)
FDA (6259)
Job Trends (6182)
News (150005)
Policy (14005)
Tag
Academia (435)
Alliances (23071)
Alzheimer's disease (346)
Approvals (6249)
Artificial intelligence (56)
Bankruptcy (143)
Best Places to Work (4299)
Biosimilars (38)
Biotechnology (44)
Breast cancer (38)
Cancer (276)
Career advice (404)
Cell therapy (39)
Clinical research (30301)
Collaboration (124)
Compensation (55)
COVID-19 (746)
C-suite (42)
Data (271)
Diabetes (45)
Diagnostics (1228)
Drug pricing (56)
Earnings (31337)
Employer resources (43)
Events (36601)
Executive appointments (143)
FDA (6418)
Funding (86)
Gene therapy (58)
GLP-1 (284)
Government (1262)
Healthcare (3516)
Infectious disease (762)
Inflammatory bowel disease (45)
Interviews (58)
IPO (5806)
Job creations (2048)
Job search strategy (372)
Layoffs (166)
Legal (3408)
Lung cancer (43)
Manufacturing (83)
Medical device (1259)
Medtech (1261)
Mergers & acquisitions (9528)
Metabolic disorders (150)
Neuroscience (434)
NextGen Class of 2024 (1580)
Non-profit (589)
Northern California (370)
Obesity (95)
Opinion (108)
Patents (50)
People (28392)
Pharmaceutical (64)
Phase I (7879)
Phase II (12811)
Phase III (11516)
Pipeline (95)
Podcasts (38)
Policy (43)
Postmarket research (1399)
Preclinical (3160)
Radiopharmaceuticals (116)
Rare diseases (77)
Real estate (2629)
Regulatory (9796)
Research institute (562)
Resumes & cover letters (55)
Southern California (374)
Startups (1624)
United States (3732)
Vaccines (108)
Weight loss (75)
Date
Today (75)
Last 7 days (275)
Last 30 days (1008)
Last 365 days (12768)
2024 (10887)
2023 (14245)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12423)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
Location
Africa (312)
Arizona (39)
Asia (19742)
Australia (2550)
California (857)
Canada (548)
China (95)
Connecticut (36)
Europe (38680)
Florida (121)
Illinois (95)
Indiana (79)
Kansas (50)
Maryland (138)
Massachusetts (765)
Minnesota (48)
New Jersey (369)
New York (243)
North Carolina (266)
Northern California (370)
Ohio (35)
Pennsylvania (255)
South America (498)
Southern California (374)
Texas (115)
Washington State (63)
260,542 Results for "dizal pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal announced new findings from a biomarker study in non-small cell lung cancer patients with exon 20 insertion mutations, highlighting sunvozertinib as an effective treatment for this patient population.
May 24, 2024
·
6 min read
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Dizal (SSE:688192) announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 through June 4 in Chicago.
April 24, 2024
·
6 min read
Dizal’s Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
Dizal announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer patients with EGFR exon 20 insertion mutations were published in the peer-reviewed journal The Lancet Respiratory Medicine.
December 13, 2023
·
6 min read
Business
Anova Partners with Dizal (Jiangsu) Pharmaceuticals to Accelerate Development of DZD9008 for Patients with Advanced or Metastatic NSCLC with EGFR Exon20 insertion Mutation
Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, and the industry’s first collaborative ‘learning system’, today announced a partnership with Dizal Pharmaceuticals (Dizal) to accelerate the development of DZD9008 for patients with EGFR Exon20ins mutant NSCLC.
September 6, 2023
·
4 min read
Dizal’s Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
Dizal presented the full analysis of the multinational pivotal study of golidocitinib for r/r PTCL in an oral presentation at the 65th American Society of Hematology Annual Meeting and Exposition.
December 10, 2023
·
7 min read
Dizal Highlights Its Advances in Hematological Portfolio at 2023 ASH, Featuring Breakthroughs in Lymphoma Treatment
Dizal announced that it will have four presentations from its hematological oncology pipeline, including golidocitinib and DZD8586, at the 65th American Society of Hematology Annual Meeting and Exposition.
November 3, 2023
·
7 min read
Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL
Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).
September 14, 2023
·
4 min read
Dizal’s Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations
Dizal today announced that sunvozertinib has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations.
August 23, 2023
·
7 min read
Dizal’s Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting
Dizal announced that data from its oncology portfolio will be presented at the 2023 American Society of Clinical Oncology Annual Meeting, June 2-6, 2023 in Chicago.
May 25, 2023
·
7 min read
Dizal Leads China’s Biotech Innovation by Showcasing Strength of its Oncology Pipeline at 2023 ASCO
Dizal presented compelling data of its robust oncology portfolio at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023, in Chicago.
June 7, 2023
·
12 min read
1 of 26,055
Next